Autologous Cd30.Car-T
Classical Hodgkin Lymphoma
Tessa TherapeuticsCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
62 Active assets in the Classical Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DACARBAZINE City of Hope Medical Center | Phase 3 | BB |
VINBLASTINE University of Washington | Phase 2 | BB |
ETOPOSIDE Masonic Cancer Center, University of Minnesota | Phase 3 | BB |
Inno-206 Michael Spinner, MD | Phase 3 | BB |
Tislelizumab Children's Cancer Group, China | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Autologous Cd30.Car-T is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →